Biotech News

Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call

Charles River (CRL)Charles River2026-06-25 13:46 ESTFDA / regulatory

WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 21, 2026-- Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2025 financial results and provide 2026 guidance on Wednesday, February 18 th , before the market opens.

Open original release

Related news

Charles River

Charles River is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

Stock data

Close
Market cap
Exchange
NYSE
Sector
Biotechnology
Location
United States